Ignite Creation Date:
2024-05-05 @ 10:54 PM
Last Modification Date:
2024-10-26 @ 10:26 AM
Study NCT ID:
NCT01218477
Status:
COMPLETED
Last Update Posted:
2016-06-17
First Post:
2010-10-08
Brief Title:
Dasatinib Combination Therapy With the Smoothened SMO Inhibitor BMS-833923 in Chronic Myeloid Leukemia CML
Sponsor:
Bristol-Myers Squibb
Organization:
Bristol-Myers Squibb
Study Overview
Official Title:
Dasatinib BMS-354825 Combined With SMO Inhibitor BMS-833923 XL139 in CML With Resistance or Suboptimal Response to a Prior TKI
Status:
COMPLETED
Status Verified Date:
2016-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of the study is to determine the safety and tolerability of the combination of BMS-833923 plus dasatinib in patients with chronic myeloid leukemia
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2010-019480-11 | EUDRACT_NUMBER | None | None |